Technical Analysis for SPHRY - Starpharma Hldgs ADR

Grade Last Price % Change Price Change
grade C 8.15 -3.55% -0.3000
SPHRY closed down 3.55 percent on Friday, January 17, 2020, on 66 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical SPHRY trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 50 DMA Bullish -3.55%
Stochastic Buy Signal Bullish -3.55%
Narrow Range Bar Range Contraction -3.55%
Gapped Up Strength -3.55%
Oversold Stochastic Weakness -3.55%
Narrow Range Bar Range Contraction 1.62%
Older signals for SPHRY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company based in Australia with established commercial partnerships and products launched, or nearing launch, within the pharmaceutical, sexual health and agrochemical sectors. Starpharma has developed a diverse portfolio of compelling products based on an underlying technology built around dendrimers. Starpharma's most advanced products are based on VivaGel (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel has been developed as two discrete products for bacterial vaginosis (BV), firstly for the treatment of BV, and secondly, for the prevention of recurrent BV. These breakthrough products target areas of significant unmet medical need in high-value markets. The VivaGel range includes the world™s first and only antiviral condom (licensed to several partners). Starpharma revolutionary DEP technology is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP versions of existing drugs, particularly in the area of anti-cancer. DEP partnerships include multiple programs with AstraZeneca and other world leading pharmaceutical companies. Starpharma also has agrochemical programs to enhance agricultural formulations. Starpharma has an IP portfolio of 100+ patents. The Starpharma HQ and research facilities are located in Melbourne Australia.
Health Medical Specialties Biopharmaceutical Pharmaceuticals Pharmaceutical Pharmaceutical Industry In China Astrazeneca Antiseptics Sexually Transmitted Diseases And Infections Bacterial Vaginosis Prevention Of Hiv/Aids Dendrimer Dendrimers Dep Technology Microbicides Microbicides For Sexually Transmitted Diseases Starpharma Hq Underlying Technology

Is SPHRY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 11.87
52 Week Low 6.61
Average Volume 1,518
200-Day Moving Average 8.8288
50-Day Moving Average 8.2378
20-Day Moving Average 8.5163
10-Day Moving Average 8.2745
Average True Range 0.2613
ADX 12.27
+DI 39.4926
-DI 50.0123
Chandelier Exit (Long, 3 ATRs ) 8.5201
Chandelier Exit (Short, 3 ATRs ) 8.7839
Upper Bollinger Band 9.2026
Lower Bollinger Band 7.8300
Percent B (%b) 0.23
BandWidth 16.1173
MACD Line -0.0721
MACD Signal Line -0.0196
MACD Histogram -0.0525
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.1500
Resistance 3 (R3) 8.1500 8.1500 8.1500
Resistance 2 (R2) 8.1500 8.1500 8.1500 8.1500
Resistance 1 (R1) 8.1500 8.1500 8.1500 8.1500 8.1500
Pivot Point 8.1500 8.1500 8.1500 8.1500 8.1500
Support 1 (S1) 8.1500 8.1500 8.1500 8.1500 8.1500
Support 2 (S2) 8.1500 8.1500 8.1500 8.1500
Support 3 (S3) 8.1500 8.1500 8.1500
Support 4 (S4) 8.1500